Quirina dos Santos-Costa
PhD (2014) in Pharmacy (Microbiology), Universidade de Lisboa
Assistant Professor, Department of Microbiology and Immunology
Appointed Director of Biosafety Level 3 Facility (BSL3), Faculdade de Farmácia da Universidade de Lisboa, Portugal (FFULisboa)
Health and Safety FFULisboa Committee member
Faculdade de Farmácia, Universidade de Lisboa — Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
Our main goal is to study and develop an innovative HIV therapeutics formulation for transdermal delivery of enfuvirtide (T-20) that is non-invasive, painless and comfortable, with the aim of increasing therapeutic adherence without the inconveniences of the injectable form.
This new concept will bring clear societal and clinical benefits in the treatment of HIV/AIDS infection, namely in improving the quality of life of people living with HIV/AIDS, especially children and older adults.
Azevedo-Pereira JM*, Santos-Costa Q. HIV Interaction With Human Host: HIV-2 As a Model of a Less Virulent Infection. AIDS Reviews 2016; 18: 44-53.
Santos-Costa Q, Lopes MM, Calado M, Azevedo-Pereira JM.* HIV-2 interaction with cell coreceptors: Amino acids within the V1/V2 region of viral envelope are determinant for CCR8, CCR5 and CXCR4 usage. Retrovirology 2014; 11: 99.lent Infection. AIDS Reviews 2016; 18: 44-53.
Espirito-Santo M, Santos-Costa Q, Calado M, Dorr P, Azevedo-Pereira JM. Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors. AIDS Res Hum Retroviruses 2012; 28: 478-485.
Calado M, Matoso P, Santos-Costa Q., Espirito-Santo M, Machado J, Rosado L, Antunes F, Mansinho K, Lopes M. M., Maltez F., Santos-Ferreira MO, Azevedo-Pereira JM. Coreceptor usage by HIV-1 and HIV-2 primary isolates: The relevance of CCR8 chemokine receptor as an alternative coreceptor. Virology 2010, 408: 174-182.
Azevedo-Pereira JM, Santos-Costa Q, Mansinho K, J. Moniz-Pereira J. Identification and characterization of HIV-2 strains obtained from asymptomatic patients that do not use CCR5 or CXCR4 coreceptors. Virology 2003; 313: 136-146